Highlights from

ECCO 2019

European Crohn's and Colitis Organisation's 14th congress

Copenhagen 6-9 March 2019

ZNF133 associated with infliximab response

Korean scientists identified clinical and genetic markers associated with infliximab response in patients with inflammatory bowel disease (IBD) [1]. Korean IBD patients (n=139) who were treated with infliximab were classified as either: primary response vs non-response, or sustained response vs loss of response. An association study was conducted using whole-exome sequencing data to identify genetic variants associated with infliximab response. Candidate variants were validated in 77 German patients with IBD.

Five candidate variants were found that were associated with primary non-response to infliximab (P<5×10−6). Of these variants, rs2228273 in ZNF133 was validated in German patients (combined P=6.49×10−7). The best genetic variant associated with loss of infliximab response was rs9144 (P=4.60×10−6). In multi-variate regression analysis, rs2228273 (P=2.10×10−5), concurrent azathioprine/6-mercaptopurine use, and body weight at the first infliximab use (<50 kg) were associated with primary non-response. In addition, the Crohn’s disease activity index (CDAI) at the time of first infliximab use, as well as rs9144 (P=0.001), were independently associated with loss of response in Crohn’s disease patients. These findings could provide insights to maximise the efficacy of infliximab therapy in IBD.

Keywords: Crohn’s disease, sequencing

  1. Jung ES, et al. ECCO 2019, DOP55.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.